PHARM — Pharmiva AB (publ) Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End null | Unit | null | null | null | null | null | nullE | nullE | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharmiva AB (publ) is a Sweden-based medical technology company within FemTech that is focused on research and development of medical products. Pharmiva AB (publ) aims to improve vaginal health and reduce the risk of complications by offering treatments without antibiotics. The company's first product Vernivia is antibiotic- and prescription-free treatment for bacterial vaginosis (BV). The treatment is based on Pharmiva AB's (publ) patented drug delivery platform, Venerol, which contains naturally occurring ingredients. The company has received CE marking class IIa for Vernivia, which means that Pharmiva AB (publ) has the right to sell and market the product within the EEA. Pharmiva AB (publ) is also ISO-certified according to ISO 13485 current design, production, marketing and sales.
Directors
- Last Annual
- Last Interim
- Incorporated
- March 12th, 2015
- Public Since
- March 31st, 2021
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Address
- Scheelevagen 4, LUND, 223 81
- Web
- https://pharmiva.com/en/home/
- Phone
- +46 462865100
- Auditors
Upcoming Events for PHARM
Similar to PHARM
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cline Scientific AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 18:17 UTC, shares in Pharmiva AB (publ) are trading at SEK0.56. This share price information is delayed by 15 minutes.
Shares in Pharmiva AB (publ) last closed at SEK0.56 and the price had moved by -62.03% over the past 365 days. In terms of relative price strength the Pharmiva AB (publ) share price has underperformed the FTSE Global All Cap Index by -63.94% over the past year.
There is no consensus recommendation for this security.
Pharmiva AB (publ) does not currently pay a dividend.
Pharmiva AB (publ) does not currently pay a dividend.
Pharmiva AB (publ) does not currently pay a dividend.
To buy shares in Pharmiva AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK0.56, shares in Pharmiva AB (publ) had a market capitalisation of .
Here are the trading details for Pharmiva AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: PHARM
Based on an overall assessment of its quality, value and momentum Pharmiva AB (publ) is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmiva AB (publ). Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -51.32%.
As of the last closing price of SEK0.56, shares in Pharmiva AB (publ) were trading -53.29% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pharmiva AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Pharmiva AB (publ)'s directors